Möchten Sie immer auf dem neuesten Stand bleiben?

Exicure enters co-development agreement with Adbiotech to advance Burixafor (GPC-100) combination therapies across multiple indications.

- Firefly’s total brain scan volumes have increased sequentially by higher percentages in each of the past four quarters - - Firefly is harnessing increased data and NVIDIA L40S GPU acceleration to...

PORTLAND, Ore., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Hemex Health, a medical diagnostics company focused on decentralized testing for blood-based conditions, today announced that the U.S. Food and Drug...

Exton, PA, Feb. 05, 2026 (GLOBE NEWSWIRE) -- New research from Spherix Global Insights underscores the profound and multifaceted burden faced by patients living with sickle cell disease (SCD),...

EXTON, PA, Aug. 06, 2025 (GLOBE NEWSWIRE) --  According to the latest findings from Spherix Global Insights’ syndicated Market Dynamix™ service, the US sickle cell disease (SCD) market is...

EXTON, PA, May 01, 2025 (GLOBE NEWSWIRE) -- Patients with sickle cell disease (SCD) continue to face severe complications, despite advances in treatment that have helped mitigate some risks....

DENVER, Dec. 23, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of...

DENVER, Nov. 15, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of...

DENVER, Oct. 15, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of...

DENVER , Oct. 08, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of...